8. Skoulidis Ferdinandos, Li Bob T, Dy Grace K, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation.[J] .N Engl J Med, 2021, 384: 2371-2381.4. 9. Jänne Pasi A, Riely Gregory J, Gadgeel Shirish M, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a K...
8. Chida K, Kotani D, Masuishi T, et al. The prognostic impact of KRAS G12C mutation in patients with metastatic colorectal cancer: a multicenter retrospective observational study. Oncologist. 2021;26(10):845-853. 9. Skoulidis F, ...
[2] Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS G12C somatic mutations across race, sex, and cancer type. N Engl J Med 2021 [3] New research uncovers how cancers with common gene mutation develop resistance to targeted drugs（来源：Dana-Farber 癌症研究所）
19. Klempner SJ, Weiss J, Pelster M, et al. KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol. 2022;33(suppl 7):S808-S869. 20. Ramalingam S, Fakih M...
在非小细胞肺癌、结直肠癌、胰腺癌、胃癌,以及胆道肿瘤等肿瘤中均存在KRAS G12C突变,但是占比较低。如果能针对KRAS突变进行治疗,则很多类型的肿瘤患者都有可能获得更好的治疗效果。以前认为KRAS不能成药,经过大家多年的努力,终于能在...
[2] Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS G12C somatic mutations across race, sex, and cancer type. N Engl J Med 2021 [3] New research uncovers how cancers with common gene mutation develop resistance to targeted drugs(来源:Dana-Farber 癌症研究所) ...
KRAS G12C mutationNon-small-cell lung cancerSotorasibLung cancer remains a significant health challenge, characterized by aberrant tissue growth within the pulmonary system. Early carcinogenic events often involve genomic instability and the emergence of a mutator phenotype. In this study, we aimed ...
3%到4%的结直肠癌病例携带KRAS G12C突变,这与预后不良有关。港安健康国际医疗介绍,在2024年AACR年会上公布并同时发表在《癌症发现》(CancerDiscovery)上的1/2期KRYSTAL-1试验(NCT03785249)的汇总结果显示,Adagrasib+Cetuximab(Krazati+Erbitux)双靶向疗法在既往接受过治疗的KRAS G12C突变局部晚期或转移性结直肠癌...
[2] Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS G12C somatic mutations across race, sex, and cancer type. N Engl J Med 2021 [3] New research uncovers how cancers with common gene mutation develop resistance to targeted drugs(来源:Dana-Farber 癌症研究所) ...
北卡罗来纳大学开发了一个20基因模型,可评估肿瘤患者是否真正依赖KRAS,以及是否能从KRAS G12C抑制剂治疗中获益。 尽管尚未在临床试验中评估该模型的预测效果,但由北卡罗来纳大学肿瘤学系医学副教授Chad Pecot领导的研究,希望KRAS抑制剂开发的制药公司,能够关注基因特征识别KRAS抑制剂应答患者的性能。